Prilactone®, the world's first aldosterone antagonist licensed for the treatment of canine heart disease, has been introduced by CEVA Animal Health.

Clinical trials have demonstrated that the product, which contains spironolactone, can improve quality of life and help to reduce the mortality risk in canine heart disease patients.

Fraser Broadfoot BVetMed GPCert(SAP) MRCVS explains "Spironolactone is considered as part of standard disease therapy in humans, where studies have demonstrated a 30% reduction in the risk of mortality when it is used in addition to ACE inhibitors and furosemide. The results of clinical trials performed by CEVA Santé Animale have demonstrated even more dramatic benefits in the dog. In short, the trials show that dogs with heart failure receiving Prilactone®, in combination with an ACE inhbitor and furosemide, demonstrated a 65% reduction in the risk of mortality compared with dogs receiving a placebo. Their quality of life was also improved."
The beef-flavoured tablets are scored for easy breaking and come in three sizes for the precise dosing of all sizes of dog. In addition, the medication only needs to be given once daily with food and is designed to be given alongside standard first-line therapy for heart disease.

For further information about Prilactone®, please contact CEVA Animal Health on (01494) 781510.

Note 1 CEVA registration dossier. The trials were carried out on 221 dogs diagnosed with heart disease. The animals treated with Prilactone®, in conjunction with ACE inhibitors and /or furosemide over a period of 14-15 months, demonstrated a three times reduction in the risk of death compared with the placebo group.
Note 2 Wood Mackenzie, Cardiovascular Insight, July 2007

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.